Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vasopressin vs norepinephrine after pulmonary endarterectomy
2025-525153-39-00Phase 3Authorised
- Sponsor
- Fondation Hôpital Saint-Joseph
- Start
- May 2026
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in chronic thromboembolic pulmonary hypertension (CTEPH) comparing Vasopressin arm with Norepinephrine arm (2 arms). Primary endpoint: Postoperative mean pulmonary arterial pressure at end of skin closure. Planned start May 2026; status: authorised.
02
Drugs
vasopressinnorepinephrine
03
Conditions
chronic thromboembolic pulmonary hypertension (CTEPH)
Beyond the preview
Go deeper on 2025-525153-39-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-525153-39-00.